Natera

Oncology Pathology Assistant - Part Time Evenings

United States

Natera Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Part TimeJob Type
UnknownVisa
Biotechnology, Healthcare, GenomicsIndustries

Requirements

Candidates must possess a Bachelor’s degree or higher, along with certification as a Pathologists' Assistant, Cytotechnologist by the American Society of Clinical Pathology (ASCP), or equivalent board. A minimum of 5 years of experience in anatomic pathology, including extensive knowledge of solid tumor pathology, is required.

Responsibilities

The Oncology Pathology Assistant will assist the Signatera team as a subject matter expert in reviewing clinical pathology reports, interpreting oncology pathology reports to identify optimal samples for MRD testing, curate clinical history and specimen information in databases, devise data stratification strategies, maintain proficiency with WHO guidelines, serve as a subject matter expert for various teams, alert the Laboratory Director to suboptimal sample collection, assist Genetic Counseling and Customer Experience teams in sample procurement, provide support for the Clinical Trial team, and perform other duties as assigned.

Skills

Pathology
Anatomic Pathology
Clinical Pathology
Data Analysis
Data Curation
Sample Database Management
WHO Guidelines
FFPE
MRD Testing
Oncology

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Key Metrics

Austin, TexasHeadquarters
2004Year Founded
$149.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Flexible medical plans
Investment options
Time off
Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
New Prospera Heart features may face slow adoption by healthcare providers.
Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
AI integration enhances accuracy and speed of Natera's cfDNA analysis.
Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI